Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer

Journal of the National Cancer Institute

Volumn 97, Issue 9, 2005, Pages 666-674

  Lorigan, Paul ^a,e   Woll, Penella J ^a,b   O'Brien, M E R ^c   Ashcroft, Linda F ^e   Sampson, Mark R ^d   Thatcher, Nick ^e  

^a WESTON PARK HOSPITAL   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d AMGEN LTD   (United Kingdom)

^e CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ETOPOSIDE; IFOSFAMIDE; MESNA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; ICE PROTOCOL 3;

ADULT; AGED; ARTICLE; BLOOD AUTOTRANSFUSION; BLOOD TOXICITY; BRAIN DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; ESOPHAGITIS; FEMALE; HEMATOPOIETIC SYSTEM; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NEUTROPENIC SEPSIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SEPSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; AUTOTRANSPLANTATION; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG ADMINISTRATION; HEMATOPOIETIC STEM CELL; HOSPITALIZATION; INCIDENCE; LUNG TUMOR; MIDDLE AGED; SMALL CELL CARCINOMA; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SMALL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; FILGRASTIM; HEMATOPOIETIC STEM CELLS; HUMANS; IFOSFAMIDE; INCIDENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 18344374561     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/dji114     Document Type: Article

References (53)

1. Cohen M, Creaven P, Fossieck B, Broder L, Selawry O, Johnson A, et al. Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treatment Rep 1977;61:349-54.
2. Arriagada R, Le Chevalier T, Pignon JP, Riviere A, Monnet I, Chomy P, et al. Initial chemotherapeutic doses and survival of patients with limited SCLC. N Engl J Med 1993;329:1848-52.
3. Ettinger D, Finkelstein D, Abeloff M, Ruckdeschel J, Aissuers S, Eggleston J. A randomised comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive stage small-cell lung cancer. J Clin Oncol 1990;8:230-40.
4. Cullen M, Morgan D, Gregory W, Robinson M, Cox D, McGivern D, et al. Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: a randomised, controlled trial. Cancer Chemother Pharmacol 1986;17:157-60.
5. Medical Research Council Lung Cancer Working Party. Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Br J Cancer 1989;59:584-90.
6. Giaccone G, Dalesio O, McVie G, Kirkpatrick A, Postmus P, Burghouts J, et al. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1993; 11: 1230-40.
7. Spiro S, Souhami R, Geddes D, Ash C, Quinn H, Harper P, et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research campaign trial. Br J Cancer 1989;59:578-83.
8. Lebeau M, Chastang C, Allard P, Migueres J, Boita H, Fichet D. Six versus 12 cycles for complete responders to chemotherapy in small cell lung cancer: definitive results of a randomised clinical trial. Eur Respir J 1992;5: 286-90.
9. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, et al. Reduction by granulocyte colony stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. New Engl J Med 1991;325:164-70.
10. Trillet-Lenoir V, Green J, Manegold C, Von Pawel J, Gatzemeier U, Lebeau B, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A:319-24.
11. Fukuoka M, Masuda M, Negoro S, Matsui K, Yana T, Kudoh S, et al. CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. Br J Cancer 1997;75:306-9.
12. Woll PJ, Hodgetts J, Lomax L, Bildet F, Cour-Chabernaud V, Thatcher N. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomised controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol 1995;13:652-9.
13. Steward W, von Pawel J, Gatzemeier U, Woll P, Thatcher N, Koschel G, et al. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of VICE chemotherapy in small-cell lung cancer (SCLC): a prospective randomised study of 300 patients. J Clin Oncol 1998;16:642-50.
14. Thatcher N, Girling D, Hopwood P, Sambrook R, Qian W, Stephens R. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony stimulating factor support: results of a British MRC multi-centre randomised trial. J Clin Oncol 2000;18:395-404.
15. James L, Gower N, Rudd R, Spiro S, Harper P, Trask C, et al. A randomised trial of low-dose/high-frequency chemotherapy as palliative treatment of poor-prognosis small-cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 1996;73:1563-8.
16. Pujol JL, Douillard JY, Riviere A, Quoix E, Lagrange JL, Berthaud P, et al. Dose intensity with four drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony stimulating factor in extensive stage small-cell lung cancer: a multi-centre randomised phase III trial. J Clin Oncol 1997;15:2082-9.
17. Ardizzoni A, Tjan-Heijnen V, Postmus P, Buchholz E, Biesma B, Karnicka-Mlodkowska H, et al. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organisation for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. J Clin Oncol 2002;20:3947-55.
18. Bonomi P. Review of selected randomized trials in small-cell lung cancer. Semin Oncol 1998;25(4 Suppl 9):70-8.
19. Janne P, Freidlin B, Saxman S, Johnson D, Livingston R, Shepherd F, et al. Twenty five years of clinical research for patients with limited stage small-cell lung cancer in North America. Cancer 2002;95:1528-32.
20. Sundstrøm S, Bremnes R, Kaasa S, Aasebø U, Hatlevoll R, Dahle R, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002;20: 4665-72.
21. Chute J, Chen T, Feigal E, Simon R, Johnson B. Twenty years of Phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999;17:1794-801.
22. Pujol J, Corestia L, Daures J. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomised trials of cisplatin containing regimen versus a regimen without this alkylating agent. Br J Cancer 2000;83:8-15.
23. Bunn P. Review of therapeutic trials of carboplatin in lung cancer. Semin Oncol 1989;16(2 Suppl 5):27-33.
24. Gatzemeier U, Hossfeld D, Neuhauss R, Reck M, Achterrath W, Lennaz L, et al. Phase II and III studies with carboplatin in small-cell lung cancer. Semin Oncol 1992;19(1 Suppl 2):28-36.
25. Thatcher N, Lind M. Carboplatin in small-cell lung cancer. Semin Oncol 1990; 17(1 Suppl 2):40-8.
26. Kosmidis P, Samantas E, Fountzilas G, Pavlidis N. Cisplatin etoposide versus carboplatin etoposide chemotherapy and irradiation in small-cell lung cancer: a randomised phase 3 trial. Semin Oncol 1994;21:23-30.
27. Lorigan P, Lee SM, Betticher D, Woodhead M, Weir D, Hanley S, et al. Chemotherapy with vincristine/ifosfamide/carboplatin/etoposide in small cell lung cancer. Semin Oncol 1995;22(3 Suppl 7):32-41.
28. Thatcher N, Qian W, Girling D. Ifosfamide, carboplatin and etoposide with mid-cycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: results of a MRC randomised trial (LU21). Proc Am Soc Clin Oncol 2003;22:2489.
29. Pettengell R, Woll PJ, Thatcher N, Dexter M, Testa N. Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of haemopoietic progenitors in whole blood. J Clin Oncol 1995;13:148-56.
30. Woll PJ, Thatcher N, Lomax L, Hodgetts J, Lee SM, Burt P, et al. Use of haemopoietic progenitors in whole blood to support dose dense chemotherapy: a randomized phase II trial in small-cell lung cancer patients. J Clin Oncol 2001;19:712-9.
31. Cerny T, Blair V, Anderson H, Bramwell V, Thatcher N. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer 1987;39:146-9.
32. WHO handbook for reporting results of cancer treatment. Geneva (Switzerland): WHO; 1979.
33. Stahel RA, Ginsberg R, Havemann K, Hirsch F, Ihde D, Jassem J, et al. Staging and prognostic factors in small-cell lung cancer. Lung Cancer 1989;5:119-26.
34. Pettengell R, Woll P, O'Connor D, Dexter T, Testa N. Viability of haemopoietic progenitors from whole blood, bone marrow and leukapheresis product: effects of storage media, temperature and time. Bone Marrow Transplant 1994;14:703-9.
35. Bucholz E, Drings P, Pilz L, Manegold C. Final results from a single centre, controlled study of standard versus dose intensified chemotherapy with sequential reinfusion of haemopoietic progenitor cells in SCLC. Proc Am Soc Clin Oncol 2003;22:2572.
36. Auperin A, Arrigada R, Pignon J, le Pechoux C, Gregor A, Stephens R, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. New Engl J Med 1999;341:476-84.
37. Pignon J, Arrigada R, Ihde D, Johnson D, Perry M, Souhami R, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. New Engl J Med 1992;327:1618-24.
38. Murray N, Coy P, Pater J, Hodson I, Arnold A, Zee B, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited stage SCLC. The NCIC Clinical Trials Group. J Clin Oncol 1993;1:336-44.
39. Work E, Nielsen O, Bentzen S Fode K, Palshof T. Randomised study of initial versus late chest irradiation in limited stage SCLC. Aarhus Lung Cancer Group. J Clin Oncol 1997;1:3030-7.
40. Perry MC, Herndon JE III, Eaton WL, Green MR. Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083. J Clin Oncol 1998;16:2466-7.
41. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Initial versus delayed hyperfractionated therapy and concurrent chemotherapy in limited stage SCLC. J Clin Oncol 1997;15:893-900.
42. Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002;20:3054-60.
43. James L, Spiro S, O'Donnell K, Rudd R, Clarke P, Trask C, et al. A randomised study of timing of thoracic irradiation in small-cell lung cancer - Study 8. Lung Cancer 2003;41 (Suppl 2):69.
44. Turissi A, Kim K, Blum R, Sauve W, Livingston R, Komaki R, et al.Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. New Engl J Med 1999;340:265-71.
45. Schild S, Brindle J, Geyer S, Krook J, Kugler J, Mailliard J, et al. Long term results of a phase III trial comparing once a day radiotherapy or twice a day radiotherapy in limited stage small-cell lung cancer. Lung Cancer 2003;41 (Suppl 2):68.
46. Bonner J, Hillman S, Vigliottii A, Kozelsky T, Marks R, Frank A, et al. High dose, twice daily thoracic radiotherapy with daily chemotherapy in limited stage small-cell lung cancer. Lung Cancer 2003;41 (Suppl 2):73.
47. Fried D, Morris D, Poole C, Rosenman J, Halle J, Detterbeck F, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited stage small-cell lung cancer. J Clin Oncol 2004;22:4785-92.
48. Pijls-Johannesma MCG, De Ruysscher DKM, Lambin P, Rutten I, Vansteenkiste JF. Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev 2005:25;CD004700.
49. Hand S, Baker J, Smith P, Macbeth F. Outpatient intensive chemotherapy for small-cell lung cancer: five years experience with modified 'ICE' ifosfamide, carboplatin and etoposide. Clin Oncol 2002;14;367-71.
50. Gharenhbaghian A, Haque K, Truman C, Evans R, Morse R, Newman J, et al. Effects of autologous salvaged blood on postoperative natural killer cell precursor frequency. Lancet 2004;363:1205-30.
51. Medical Research Council Lung Cancer Working Party. Comparison of oral etoposide and standard intravenous multi-drug chemotherapy for small-cell lung cancer: multicentre randomised trial. Lancet 1996;348:563-6.
52. Souhami R, Spiro S, Rudd RM, Ruiz de Elviva M, James L, Gower N, et al. Five day oral etoposide for advanced small-cell lung cancer: randomised comparison with intravenous chemotherapy. J Natl Cancer Inst 1997;89:577-80.
53. Earl H, Rudd R, Spiro S, Ash C, James L, Law C, et al. Randomised trial of planned versus as required chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 1991;64:566-72.